Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21355789 | 0.81 | KLKB1 (0.41) | KLKB1MCHR1METTL3DGAT1SCN10A | |
| SCHEMBL23088235 | 0.79 | METTL3 (0.38) | KLKB1METTL3DGAT1 | |
| SCHEMBL21354783 | 0.78 | METTL3 (0.35) | KLKB1METTL3DGAT1 | |
| SCHEMBL23088694 | 0.78 | METTL3 (0.35) | KLKB1METTL3DGAT1 | |
| SCHEMBL27030124 | 0.75 | SCN10A (0.39) | KLKB1MCHR1METTL3DGAT1SCN10A | |
| SCHEMBL23088668 | 0.75 | KLKB1 (0.54) | KLKB1 | |
| SCHEMBL24738129 | 0.75 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL21354921 | 0.74 | KLKB1 (0.40) | KLKB1MCHR1METTL3DGAT1PIK3CA | |
| SCHEMBL24737361 | 0.72 | METTL3 (0.43) | KLKB1MCHR1METTL3DGAT1PIK3CA | |
| SCHEMBL23088098 | 0.72 | KLKB1 (0.34) | KLKB1MCHR1METTL3DGAT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | KLKB1 1/4885MCHR1 4604/4885METTL3 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.